284.14
4.89 (1.75%)
| Previous Close | 279.25 |
| Open | 278.83 |
| Volume | 25,465 |
| Avg. Volume (3M) | 297,610 |
| Market Cap | 7,672,458,752 |
| Price / Earnings (TTM) | 10.21 |
| Price / Earnings (Forward) | 28.41 |
| Price / Sales | 3.04 |
| Price / Book | 1.04 |
| 52 Weeks Range | |
| Earnings Date | 30 Apr 2026 |
| Profit Margin | -85.16% |
| Operating Margin (TTM) | 9.72% |
| Diluted EPS (TTM) | -76.53 |
| Quarterly Revenue Growth (YOY) | -4.20% |
| Quarterly Earnings Growth (YOY) | -83.30% |
| Total Debt/Equity (MRQ) | 20.50% |
| Current Ratio (MRQ) | 5.99 |
| Operating Cash Flow (TTM) | 515.30 M |
| Levered Free Cash Flow (TTM) | 250.23 M |
| Return on Assets (TTM) | 1.55% |
| Return on Equity (TTM) | -27.52% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Medical Devices (US) | Mixed | Bearish |
| Medical Devices (Global) | Mixed | Bearish | |
| Stock | Bio-Rad Laboratories, Inc. | Mixed | Bearish |
AIStockmoo Score
| Analyst Consensus | NA |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 2.0 |
| Average | 0.00 |
|
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (56% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (44% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (42% of 2023 sales), Europe (31%), Asia (31%), and other (6%). Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing. |
|
| Sector | Healthcare |
| Industry | Medical Devices |
| Investment Style | Small Core |
| % Held by Insiders | 16.14% |
| % Held by Institutions | 93.04% |
No data within this time range.
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| EDWARDS JEFFREY L | - | - | 0 | 0 |
| HINCKLEY GREG K | - | - | 0 | 0 |
| PEI MELINDA LITHERLAND | - | - | 0 | 0 |
| PINKSTON ARNOLD A | - | - | 0 | 0 |
| Aggregate Net Quantity | 0 | |||
| Aggregate Net Value ($) | 0 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | - | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| PINKSTON ARNOLD A | Director | 21 Apr 2026 | Option execute | 407 | - | - |
| EDWARDS JEFFREY L | Director | 21 Apr 2026 | Option execute | 407 | - | - |
| PEI MELINDA LITHERLAND | Director | 21 Apr 2026 | Option execute | 407 | - | - |
| HINCKLEY GREG K | Director | 21 Apr 2026 | Option execute | 407 | - | - |
| Date | Type | Details |
|---|---|---|
| 29 Jan 2026 | Announcement | Bio-Rad to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 12, 2026 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |